From Yahoo Finance: 2025-04-01 12:42:00

Gene editing stocks are in the spotlight, with Vertex Pharmaceuticals (VRTX) standing out. The U.S. healthcare system is adapting to gene-editing therapies, with significant market growth projected. Breakthrough treatments for conditions like hepatitis B and hyperoxaluria show promise, while the number of patients benefiting from gene therapies is expected to rise sharply.

Financially, gene editing therapies are set to peak in spending by 2026. However, challenges like delivery risks and regulatory scrutiny persist. Vertex Pharmaceuticals is a key player in gene editing, focusing on genetic diseases like cystic fibrosis. The company’s collaboration with CRISPR Therapeutics is driving innovation in treatments for sickle cell disease and beta-thalassemia.

Vertex Pharmaceuticals’ financial results for Q4 2024 show a 16% revenue increase from the previous year, surpassing expectations. With a broad market addressing various diseases, Vertex aims to reach millions of patients globally. Despite its potential, the focus on AI stocks for higher returns remains strong. Vertex ranks 2nd on the list of best gene-editing stocks to buy.

Read more: Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?